General discussion and future perspectives 187 8 HPV DNA-positive women in populationbased cervical screening. Int J Cancer 2012; 130(3): 602-10. 48. Polman NJ, Snijders PJF, Kenter GG, Berkhof J, Meijer C. HPV-based cervical screening: Rationale, expectations and future perspectives of the new Dutch screening programme. Prev Med 2019; 119: 108-17. 49. Fontham ETH, Wolf AMD, Church TR, Etzioni R, Flowers CR, Herzig A, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin 2020; 70(5): 321-46. 50. Rebolj M, Rimmer J, Denton K, Tidy J, Mathews C, Ellis K, et al. Primary cervical screening with high risk human papillomavirus testing: observational study. BMJ 2019; 364: l240. 51. Maver PJ, Poljak M. Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans. Clin Microbiol Infect 2020; 26(5): 579-83. 52. Machalek DA, Roberts JM, Garland SM, Thurloe J, Richards A, Chambers I, et al. Routine cervical screening by primary HPV testing: early findings in the renewed National Cervical Screening Program. Med J Aust 2019; 211(3): 113-9. 53. Dijkstra MG, van Niekerk D, Rijkaart DC, van Kemenade FJ, Heideman DA, Snijders PJ, et al. Primary hrHPV DNA testing in cervical cancer screening: how to manage screen-positive women? A POBASCAM trial substudy. Cancer Epidemiol Biomarkers Prev 2014; 23(1): 55-63. 54. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol 2007; 197(4): 356.e1-6. 55. Aitken CA, van Agt HME, Siebers AG, van Kemenade FJ, Niesters HGM, Melchers WJG, et al. Introduction of primary screening using high-risk HPV DNA detection in the Dutch cervical cancer screening programme: a populationbased cohort study. BMC Med 2019; 17(1): 228. 56. RIVM. Monitor bevolkingsonderzoek baarmoederhalskanker 2020.; 2021. 57. RIVM. Newsletter Dutch Population Screening for Cervical Cancer 2022 2022. 58. Garcia F, Barker B, Santos C, Brown EM, Nuño T, Giuliano A, et al. Crosssectional study of patient- and physiciancollected cervical cytology and human papillomavirus. Obstet Gynecol 2003; 102(2): 266-72. 59. Othman NH, Zaki FH, Hussain NH, Yusoff WZ, Ismail P. SelfSampling Versus Physicians’ Sampling for Cervical Cancer Screening Agreement of Cytological Diagnoses. Asian Pac J Cancer Prev 2016; 17(7): 3489-94. 60. Loopik DL, Melchers W, Vedder J, van den Brule A, Massuger L, Bekkers R, et al. Reflex cytology for triage of high-risk human papillomavirus positive self-sampled material in cervical cancer screening: a prospective cohort study. BJOG 2020; 127(13): 1656-63. 61. Brink AA, Meijer CJ, Wiegerinck MA, Nieboer TE, Kruitwagen RF, van Kemenade F, et al. High concordance of results of testing for human papillomavirus in cervicovaginal samples collected by two methods, with comparison of a novel self-sampling device to a conventional endocervical brush. J Clin Microbiol 2006; 44(7): 2518-23. 62. Mangold BR. Self-Collected Samples in Cervical Cancer Screening: Results of HPV and Pap Self-Collected Samples Compared to Physician-Obtained Specimens. Acta Cytol 2019; 63(5): 379-84. 63. Luttmer R, De Strooper LM, Berkhof J, Snijders PJ, Dijkstra MG, Uijterwaal MH, et al. Comparing the performance of FAM19A4 methylation analysis, cytology and HPV16/18 genotyping for the detection of cervical (pre)cancer in highrisk HPV-positive women of a gynecologic
RkJQdWJsaXNoZXIy MjY0ODMw